ALLR Latest Press Releases

-- February 18, 2026 --

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need Globe Newswire 8:15 AM

-- February 3, 2026 --

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment Globe Newswire 8:00 AM

-- December 31, 2025 --

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders Globe Newswire 8:00 AM

-- November 14, 2025 --

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates Globe Newswire 9:00 AM

-- September 22, 2025 --

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software